The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $4.32

Today's change-0.25 -5.47%
Updated August 29 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $4.32

Today's change-0.25 -5.47%
Updated August 29 4:00 PM -4GMT. Delayed by at least 15 minutes.

Keryx Biopharmaceuticals Inc crosses below 20-day moving average

Keryx Biopharmaceuticals Inc closed sharply lower Monday, dropping (U.S.)$0.25 or 5.47% to (U.S.)$4.32 and crossing below its 20-day moving average. Over the last five days, shares have lost 2.26% and are down 14.46% for the last year to date. This security has underperformed the S&P 500 by 42.34% during the last year.

Key company metrics

  • Open(U.S.) $4.53
  • Previous close(U.S.) $4.57
  • High(U.S.) $4.59
  • Low(U.S.) $4.28
  • Bid / Ask(U.S.) $4.33 / (U.S.) $0.00
  • YTD % change-14.46%
  • Volume2,083,451
  • Average volume (10-day)1,266,141
  • Average volume (1-month)2,007,439
  • Average volume (3-month)1,603,856
  • 52-week range(U.S.) $2.80 to (U.S.) $7.80
  • Beta4.23
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.46
Updated August 29 4:00 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX0.29%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue9764
Total other revenue--------
Total revenue9764
Gross profit4541
Total cost of revenue6224
Total operating expense33303135
Selling / general / administrative20212220
Research & development78811
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-24-23-25-31
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-45-41-38-31
Income after tax-45-41-38-31
Income tax, total0000
Net income-45-41-38-31
Total adjustments to net income--------
Net income before extra. items-45-41-38-31
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-45-41-38-31
Inc. avail. to common incl. extra. items-45-41-38-31
Diluted net income-45-41-38-31
Dilution adjustment0--0--
Diluted weighted average shares106106105105
Diluted EPS excluding extraordinary itemsvalue per share-0.42-0.39-0.36-0.29
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.42-0.39-0.36-0.29